MyABFM vs MediMorph

The MyABFM Portfolio app is for ABFM Diplomates, residents, and other ABFM users to access their certification requirements and interact with certification activities in a mobile-friendly interface.

MediMorph performs dose conversions to make calculating equivalent doses between narcotics easy. Performing dose conversions by hand can be inaccurate and tedious, so MediMorph aims to provide a simple fix to this issue by allowing you to perform dose conversions between common narcotics with a few easy taps. Conversions are based on the gold standard resource for opiate dosing "Demystifying Opioid Conversion Calculations: A Guide for Effective Dosing" by Mary Lynn McPherson. Features: - Dose conversions between common narcotics - Conversions for both PO (oral) and IV/SQ (intravenous/subcutaneous) administration (for applicable narcotics) - Reduced dose calculation (medical literature recommends initial dose reduction of 25-50% when switching between opiates) - Display of conversion steps used to perform calculation - Local history of calculations performed - Notes, references, and disclaimer Feel free to reach out if you have any questions or feedback, and thanks for taking a look! Disclaimer: All information contained in and produced by the MediMorph application is provided for educational purposes only. The dose conversions performed by our app are approximate based on published medical literature and do not account for individual patient variables. Information provided by the MediMorph application should not be used as a substitute for clinical judgement, and should not be the basis of any clinical decisions. When using our app, we recommend referencing relevant literature and double checking the work displayed in the calculations our app performs in order to make more informed judgements. If you are not a healthcare professional, we advise checking with an anesthesiologist before making medical decisions involving narcotic administration. See the "Notes and References" page of the app for more information on our methods and the medical literature used to inform the development of the MediMorph application.